성인 진행성 파킨슨병 환자의 삶의 질 결과 평가를 위한 포스레보도파/포스카르비도파 실제 임상 연구 (PUCCINI)
고위험 파킨슨병 환자에서 Foslevodopa/Foscarbidopa의 효과성 및 안전성/내약성에 관한 글로벌 실제 임상 데이터 연구
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating adult participants earlier within advanced Parkinson disease under routine clinical practice.
Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 100 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled across approximately 40 sites across the world.
Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 6 months.
There are no additional examinations due to the study but the participants and caregivers will need to fill several questionnaires to generate data on their motor function and well-being
연구 개요
상태
상태
정황
정황
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Lars Bergmann
- 전화번호: +49(0)170 4538568
- 이메일: lars.bergmann@abbvie.com
연구 장소
-
-
-
Brasov, 루마니아, 500326
- 모병
- Spitalul Clinic Judetean De Urgenta Brasov /ID# 277499
-
-
Bucharest
-
Bucharest, Bucharest, 루마니아, 022328
- 모병
- Fundeni Clinical Institute /ID# 277490
-
-
Iaşi
-
Iași, Iaşi, 루마니아, 700620
- 모병
- Arcadia Spitale Si Centre Medicale /Id# 277525
-
-
Timiș County
-
Timișoara, Timiș County, 루마니아, 300724
- 모병
- Neurotim Med /ID# 277500
-
-
-
-
Florida
-
Boca Raton, Florida, 미국, 33486
- 모병
- Parkinson'S Disease & Movement Disorders Center Of Boca Raton /ID# 277190
-
Tampa, Florida, 미국, 33613
- 모병
- University of South Florida- Neuroscience Institute /ID# 278562
-
-
North Carolina
-
Charlotte, North Carolina, 미국, 28207-1196
- 모병
- Novant Health /ID# 278567
-
-
Texas
-
Georgetown, Texas, 미국, 78628
- 모병
- Texas Movement Disorder Specialists /ID# 278565
-
-
-
-
Barcelona
-
Sant Joan Despí, Barcelona, 스페인, 08970
- 모병
- Hospital de Sant Joan Despi Moises Broggi /ID# 276895
-
-
-
-
-
Newcastle upon Tyne, 영국, NE3 3HD
- 모병
- The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 281752
-
-
Devon
-
Plymouth, Devon, 영국, PL6 8DH
- 모병
- University Hospitals Plymouth NHS Trust /ID# 284977
-
-
Hammersmith and Fulham
-
London, Hammersmith and Fulham, 영국, W6 8RF
- 모병
- Charing Cross Hospital /ID# 284211
-
-
-
-
-
Jerusalem, 이스라엘, 91120
- 모병
- Hadassah Medical Center-Hebrew University /ID# 276211
-
-
Jerusalem
-
Jerusalem, Jerusalem, 이스라엘, 91031
- 모병
- Shaare Zedek Medical Center /ID# 276209
-
-
Tel Aviv
-
Ramat Gan, Tel Aviv, 이스라엘, 5265601
- 모병
- The Chaim Sheba Medical Center /ID# 276210
-
Tel Aviv, Tel Aviv, 이스라엘, 6423906
- 모병
- Tel Aviv Sourasky Medical Center /ID# 276212
-
-
-
-
-
Kanagawa, 일본, 231-0063
- 모병
- Noge General Medicine and Neurology /ID# 280741
-
Tokushima, 일본, 770-0852
- 모병
- Itsuki Hospital /ID# 280743
-
Tokyo, 일본, 202-0004
- 모병
- Miwa Internal Medicine Clinic /ID# 280740
-
-
Saitama
-
Iruma-gun, Saitama, 일본, 3500495
- 모병
- Saitama Medical University Hospital /ID# 280624
-
-
Tokyo
-
Bunkyo-ku, Tokyo, 일본, 113-8431
- 모병
- Juntendo University Hospital /ID# 280623
-
-
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5T 2S8
- 모병
- Toronto Western Hospital /ID# 278384
-
-
Quebec
-
Sherbrooke, Quebec, 캐나다, J1H 5N4
- 모병
- CIUSSS de l Estrie - CHUS /ID# 278379
-
-
-
-
City of Zagreb
-
Grad Zagreb, City of Zagreb, 크로아티아, 10000
- 모병
- Klinicka Bolnica Dubrava /ID# 278408
-
-
Primorje-Gorski Kotar County
-
Rijeka, Primorje-Gorski Kotar County, 크로아티아, 51000
- 모병
- Klinicki Bolnicki Centar Rijeka /ID# 278277
-
-
-
-
-
Guaynabo, 푸에르토 리코, 00969
- 모병
- Centro Internacional De Mercadeo /ID# 276088
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Participants with earlier within advanced Parkinson disease receiving Foslevodopa/Foscarbidopa treatment in accordance with the local label requirements in the participating country.
설명
Inclusion Criteria:
- Eligibility for Foslevodopa/Foscarbidopa (LDp/CDp) therapy in accordance with approved local label in the participating country and local reimbursement regulations, if applicable
- A diagnosis of levodopa-responsive idiopathic Parkinson's Disease (PD)
- Adult male or female between 18 and 69 years of age
- Disease duration (time since diagnosis) <10 years
- Time since motor fluctuations started ≤5 years
- H&Y Stage <3 in best "on"
- "off" time of ≤ 4.5 hours per day
- Naïve to LDp/CDp
- Treatment has been optimized with oral/transdermal PD medication in the opinion of the Investigator
- Decision to treat with LDp/CDp made by the clinician prior to any decision to approach the participant to participate in the study
- Willing and able to comply with procedures required during this study, specifically with entering data and filling questionnaires in an electronic device (tablet).
- Prior to any study-related procedures being performed, the participant or Legal Authorized Representative (LAR) must voluntarily sign an Authorization for Use/Disclosure of Data (AUDD)/Informed Consent Form (ICF) according to national regulations once the study has been explained and the participant has the opportunity to have any questions answered
Exclusion Criteria:
- History of any condition included in the contraindications section of the approved local Foslevodopa/Foscarbidopa (LDp/CDp) label in the participating country
- History of treatment with any Device-Aided Therapy (DAT), such as Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), Levodopa/Carbidopa Intestinal Gel (LCIG)/ Carbidopa/Levodopa Enteral Suspension (CLES), Levodopa/Entacapone/Carbidopa Intestinal Gel (LECIG)
- Mini-Mental State Examination (MMSE) score <24
- Participation in a concurrent investigational or observational clinical trial
- Lack of motivation/insufficient language skills to complete the study questionnaires
- History of significant skin conditions or disorders (e.g., psoriasis, atopic dermatitis). In case of temporary affections like recent sunburn or open wounds, or in case of permanent affections like acne, scar tissue, tattoo, branding, or colorations, the participant should not be included if the Investigator considers these as interfering with infusion of study drug or study assessments.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
|---|
|
Foslevodopa/Foscarbidopa
Participants will receive Foslevodopa/Foscarbidopa as prescribed by their physician according to local label. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change From Baseline in motor complications as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore
기간: Up to approximately 6 months
|
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore is an investigator-used rating tool to assess the motor complications of Parkinson's Disease (PD). (The numeric score for each question is between 0-4; 0=Normal, 4=Severe) |
Up to approximately 6 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change From Baseline to "Off" Time Duration (absolute hours) and Severity, as measured by the modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV, Item 4.3 and 4.4 scores
기간: Up to approximately 6 months
|
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore is an investigator-used rating tool to assess the motor complications of Parkinson's Disease (PD). (The numeric score for each question is between 0-4; 0=Normal, 4=Severe) |
Up to approximately 6 months
|
|
Change From Baseline in Dyskinesia presence, impairment and disability, as measured by Unified Dyskinesia Rating Scale (UDysRS) total score
기간: Up to approximately 6 months
|
The UDysRS total score is obtained by summing the item scores, ranging from 0 to 104. Higher scores are associated with more disability. Negative changes from baseline indicate improvement. |
Up to approximately 6 months
|
|
Change From Baseline in Dyskinesia duration (absolute hours) and severity, as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) IV, Item 4.1 and 4.2 score
기간: Up to approximately 6 months
|
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV subscore is an investigator-used rating tool to assess the motor complications of Parkinson's Disease (PD). (The numeric score for each question is between 0-4; 0=Normal, 4=Severe) |
Up to approximately 6 months
|
|
Change From Baseline in Disease-specific Quality of Life (QoL) as measured by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index
기간: Up to approximately 6 months
|
The Parkinson's Disease Questionnaire (PDQ-39) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with Parkinson's Disease (PD), and which may not be included in general health status questionnaires. Each item is scored on the following 5-point scale: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always (or cannot do at all, if applicable). |
Up to approximately 6 months
|
|
Change From Baseline in Generic Quality of Life (QoL) as measured by the EuroQol 5-Dimension Questionnaire (EQ-5D-5L)
기간: Up to approximately 6 months
|
The EuroQol 5-dimension questionnaire (EQ-5D-5L) is a standardized non-disease specific instrument for describing and valuing health-related quality of life. The EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the participant's current health state. Each item is scored from 1 (best) to 5 (worst). An increase in the EQ-5D-5L score indicates a worsening. |
Up to approximately 6 months
|
|
Change From Baseline in Motor experiences of daily living as measured by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
기간: Up to approximately 6 months
|
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's Disease (PD). Part II assesses the participant's motor experiences of daily living (M-EDL) with 13 questions. (The numeric score for each question is between 0-4; 0=Normal,1=Slight,2=Mild,3=Moderate,4=Severe). Part II scores range from 0 to 52, with higher scores indicating more severe symptoms of PD. Negative changes from Baseline indicate improvement. |
Up to approximately 6 months
|
|
Change From Baseline in Disease-specific sleep disturbances as measured by the Parkinson's Disease Sleep Scale-2 (PDSS-2) Total Score
기간: Up to approximately 6 months
|
The PDSS-2 consists of 15 questions that evaluate motor and non-motor symptoms at night and upon wakening, as well as disturbed sleep grouped into 3 domains: motor symptoms at night (5 items), Parkinson's Disease (PD) symptoms at night (5 items), and disturbed sleep (5 items). The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 [never] to 4 [very often] with the exception of Question 1 score ranging from 0 [very often] to 4 [never]). |
Up to approximately 6 months
|
|
Change From Baseline in Symptom severity measured by the Patient Global Impression of Severity (PGI-S) questionnaire.
기간: Up to approximately 6 months
|
The Patient Global Impression of Severity (PGI-S) is a single, patient-reported item that assesses the subject's perceived level of symptoms over the past 7 days. The measure uses a 5-point Likert rating scale with responses ranging from "no symptoms" (1) to "very severe" (5), with higher scores indicating greater severity. |
Up to approximately 6 months
|
|
Change From Baseline in Clinician-Reported Symptom Severity measured by the Clinical Global Impression of Severity (CGI-S) questionnaire.
기간: Up to approximately 6 months
|
Clinical Global Impression of Severity (CGI-S) is a 5-point rating scale that requires the clinician to assess the severity of the participant's illness. Scores range from 1=normal; to 5=very severe. |
Up to approximately 6 months
|
|
Change From Baseline in Patient-Reported Symptom Change measured by the Patient Global Impression of Change (PGI-C) questionnaire
기간: Up to approximately 6 months
|
The PGI-C is a participant's rating of the change in their PD-related symptoms since initiation of study drug. Participants rate their change in status using the following 7-point scale: 1 = Very much improved; 7 = Very much worse. |
Up to approximately 6 months
|
|
Change From Baseline in Clinician-Reported Symptom Change measured by the Clinical Global Impression of Change (CGI-C) questionnaire.
기간: Up to approximately 6 months
|
The Clinical Global Impression of Change (CGI-C) is a clinician's impression of a subject's change in status on a 7-point scale. CGI-C scores range from 1 = very much improved to 7 = very much worse. |
Up to approximately 6 months
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change From Baseline in morning akinesia (early morning "off") as measured by by dedicated questionnaire.
기간: Up to approximately 6 months
|
Measured by dedicated questionnaire. |
Up to approximately 6 months
|
|
Change From Baseline in the Presence and Frequency of Early Morning Dystonia, as measured by the Parkinson's Disease Sleep Scale-2 (PDSS-2) single item 12
기간: Up to approximately 6 months
|
The PDSS-2 consists of 15 questions that evaluate motor and non-motor symptoms at night and upon wakening, as well as disturbed sleep grouped into 3 domains: motor symptoms at night (5 items), Parkinson's Disease (PD) symptoms at night (5 items), and disturbed sleep (5 items). The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 [never] to 4 [very often] with the exception of Question 1 score ranging from 0 [very often] to 4 [never]). |
Up to approximately 6 months
|
|
Change From Baseline in Activities of daily living/independence as measured by the Schwab-England Activities of Daily Living (SE-ADL) Scale
기간: Up to approximately 6 months
|
The Schwab and England ADL (Activities of Daily Living) scale assesses the capabilities of people with impaired mobility. The scale uses percentages to reflect the effort and dependence on others people that are needed to complete daily chores." The results reported are between 0% (bedridden) and 100% (healthy). |
Up to approximately 6 months
|
|
Change From Baseline in Self-efficacy as measured by the Self-efficacy for Managing Chronic Disease Scale (SEMCD)
기간: Up to approximately 6 months
|
Self-efficacy for Managing Chronic Disease Scale (SEMCD) Self-efficacy for chronic disease will be measured. 6 items 1 to 10 each. 1 = not confident 10 = total confident. |
Up to approximately 6 months
|
|
Change From Baseline in Ability to Reintegrate Into Normal Social Activity After Illness as measured by the Reintegration to Normal Living Scale (RNLI) Scale
기간: Up to approximately 6 months
|
The Reintegration to Normal Living Index (RNLI) assesses how well individuals resume everyday activities and participate in their communities following illness or injury. It covers areas such as mobility, daily functioning, and self-perception, and includes 11 items scored on a 0-10 scale, with higher scores indicating greater reintegration into normal living. |
Up to approximately 6 months
|
|
Change From Baseline in Treatment satisfaction, as measured by the Treatment Satisfaction Questionnaire for Medication, 9-Item Version Score (TSQM-9)
기간: Up to approximately 6 months
|
Treatment Satisfaction Questionnaire for Medication, 9-Item Version Score. an instrument used to measure how satisfied adult patients are with their medications. The scale consists of 9 items with 5 or 7 Likert scale answering options. |
Up to approximately 6 months
|
|
Change From Baseline in Stigma as measured by the Parkinson's Disease Questionnaire-39 Items (PDQ-39) Summary Index
기간: Up to approximately 6 months
|
The Parkinson's Disease Questionnaire (PDQ-39) is a disease-specific instrument designed to measure aspects of health that are relevant to participants with Parkinson's Disease (PD), and which may not be included in general health status questionnaires. Each item is scored on the following 5-point scale: 0 = never, 1 = occasionally, 2 = sometimes, 3 = often, 4 = always (or cannot do at all, if applicable). |
Up to approximately 6 months
|
|
Healthcare Resource Utilization (HRU)
기간: Up to approximately 6 months
|
Healthcare Resource Utilization (HRU) is measured from initiation of the therapy and captures eg physician visits, hospital stays and engagement with other supporting therapists. |
Up to approximately 6 months
|
|
Number of Participants achieving monotherapy with Foslevodopa/Foscarbidopa (LDp/CDp)
기간: Up to approximately 6 months
|
Percentage of patients achieving monotherapy with LDp/CDp at month 3 and month 6 |
Up to approximately 6 months
|
|
Questionnaire to investigate the practicalities of the infusion system
기간: Up to approximately 6 months
|
Questionnaire to investigate the practicalities of the infusion system (e.g., vial consumption, frequency of infusion-site rotation, nighttime dose adjustments). |
Up to approximately 6 months
|
|
Number of Participants with Adverse Events (AEs)
기간: Up to approximately 6 months
|
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Up to approximately 6 months
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: ABBVIE INC., AbbVie
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- P25-758
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .